Opendata, web and dolomites

RITA-MI

Rituximab in Acute Myocardial Infarction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RITA-MI project word cloud

Explore the words cloud of the RITA-MI project. It provides you a very rough idea of what is the project "RITA-MI" about.

rituximab    reduces    cell    successful    cd20    acute    infarct    function    risk    cvd    zouggari    safe    benefit    reducing    circulating    validated    cardiovascular    30    mortality    ccl7    readily    cv    forget    heart    death    interestingly    mi    limit    hypothesis    erc    size    depletes    monoclonal    selective    ischemic    starting    events    first    injury    grant    disease    efficacy    pursued    diseases    co    therapies    site    myocardial    2013    mature    rapid    purposing    proof    antibody    single    initiation    followed    series    lymphocytes    inflammatory    nat    et    considerable    dose    mab    therapy    med    patients    stemi    ineffective    reduce    orchestration    morbidity    immune    25    translate    al    infarction    substantially    morbidities    breaking    scheme    monocytes    discovery    ground    therapeutic    group    cells    instrumental    improves    fire    mobilisation    re    trial    clinical    infusion    recruitment    drug    burden    intravenous    ultimate    rita    correspond    chemokine    excess   

Project "RITA-MI" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE 

Organization address
address: TRINITY LANE THE OLD SCHOOLS
city: CAMBRIDGE
postcode: CB2 1TN
website: www.cam.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙402 €
 EC max contribution 149˙402 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2015-PoC
 Funding Scheme ERC-POC
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) coordinator 15˙266.00
2    PAPWORTH HOSPITAL NHS FOUNDATION TRUST UK (CAMBRIDGE) participant 134˙136.00

Map

 Project objective

Cardiovascular diseases (CVD) represent a major cause of morbidity and mortality. The best current therapy reduces CV risk by only 25-30% and remains ineffective in reducing the excess risk associated with several co-morbidities. Therefore, there is considerable need for new therapies to limit the burden of CVD. Based on a current ERC Starting Grant project, the applicant’s group proposed and validated the concept that mature B lymphocytes are instrumental in the orchestration of the inflammatory response after ischemic myocardial injury, in part through production of CCL7 chemokine and mobilisation/recruitment of inflammatory monocytes to the infarction site (Zouggari Y et al., Nat Med 2013). Our goal now is to translate this ground-breaking discovery and novel therapeutic concept into benefit for patients. The overall objective of the RITA-MI project is to develop a new and cost-effective therapy for patients with acute myocardial infarction (MI) based on selective targeting of the B cell immune response, with the ultimate aim to substantially reduce the high risk of death and major cardiovascular events associated with the disease. Interestingly, the drug, CD20 monoclonal antibody (mAb) rituximab, is readily available for testing in a re-purposing scheme, allowing for rapid initiation of this proof-of-concept clinical trial. Working Hypothesis: A single infusion of rituximab at the acute phase of MI is safe, substantially depletes circulating B cells, and has the potential to limit infarction size and improves myocardial heart function. Overall objective: Does a ‘fire and forget’ approach with rituximab (a single intravenous infusion) reduce infarct size and/or improve heart function in patients with acute STEMI? The overall aim will be pursued through a series of specific objectives, which will correspond to a first step of a dose-finding proof-of-concept study (the present RITA-MI project), followed (if successful) by a phase II clinical efficacy trial.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RITA-MI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RITA-MI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PEGASOS (2019)

Photon Emitting Gated Arrays for Scalable On-chip quantum Systems

Read More  

Aware (2019)

Aiding Antibiotic Development with Deep Analysis of Resistance Evolution

Read More  

ENUF (2019)

Evaluation of Novel Ultra-Fast selective III-V Epitaxy

Read More